FILTER
FILTERED INTERVIEW RESULTS
David H. Crean
MANAGING DIRECTOR, INVESTMENT BANKING, OBJECTIVE CAPITAL PARTNERS
Objective Capital Partners, headquartered in Southern California, is a leading mergers and acquisitions (M&A) investment banking firm focused on transactions for privately held companies with enterprise values up to US$500 million.
Vidya Vasu-Devan
DEPUTY DIRECTOR, BILL & MELINDA GATES FOUNDATION’S STRATEGIC INVESTMENT FUND
The Bill & Melinda Gates Foundation is the largest private foundation in the United States. Its Strategic Investment Fund (SIF) works to leverage the might of the private sector to achieve progress on the foundation’s charitable objectives.
Raul Rodriguez
PRESIDENT AND CEO, RIGEL
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and commercializing novel small molecule drugs for immune and hematologic disorders, cancer and rare diseases.
Elizabeth Jeffords
CHIEF COMMERCIAL & STRATEGY OFFICER, ALKAHEST
Alkahest has a unique technology platform for elucidating changes in the plasma proteome in healthy aging and in age-related diseases.
Michael Quirmbach
CHIEF BUSINESS OFFICER, CORDENPHARMA
CordenPharma is a CDMO supporting pharma and biotech companies, with cGMP facilities across Europe & the US.
Brian Frenzel
CEO, TOSK
Tosk is developing a family of small molecule drugs to prevent the toxic side ef-fects of cancer treatments.
Alan Seem
PARTNER, JONES DAY
Jones Day is the largest law firm in the United States and one of the ten largest firms globally.
David Craford
PRESIDENT AND CEO, CYTOBANK
Cytobank is developing and commercializing the leading SaaS platform for machine learning-based analysis of high-complexity life sciences data.
Paul Tanico
CEO, NEURODIAGNOSTICS LLC
NeuroDiagnostics is focused on its DISCERN™ test for the diagnosis of Alzheimer’s disease.
Kevin Grimes
CO-DIRECTOR, SPARK TRANSLATIONAL RESEARCH PROGRAM, STANFORD UNIVERSITY
The Stanford SPARK program was established in 2006 to advance new biomedical research discoveries into promising new treatments for patients.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
